SCHEMBL6348019

SCHEMBL6348019

COc1cc(C(=O)CN(C(C)=O)C(C(N)=O)C(C)C)cc(OC)c1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
KDM4E B2RXH2 1/20 0.42
SCN1A P35498 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN3A Q9NY46 1/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.39
APOBEC3A P31941 1/20 0.39
HTT P42858 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
PDK1 Q15118 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TP53 P04637 1/20 0.37
ALOX12 P18054 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
THPO P40225 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6347885 0.89 KMT2A (0.43) KMT2AALDH1A1MEN1KDM4ESCN1A
SCHEMBL6350988 0.88 MAPT (0.46) KMT2AALDH1A1MEN1MAPK1GAA
SCHEMBL6352299 0.87 KMT2A (0.42) KMT2AALDH1A1MEN1KDM4ESCN1A
SCHEMBL6359355 0.85 TP53 (0.42) ALDH1A1MAPK1TSHRHTTL3MBTL1
SCHEMBL6352526 0.78 PARP1 (0.49) KMT2AALDH1A1
SCHEMBL6347116 0.78 CA12 (0.47) KMT2AALDH1A1MEN1GAATSHR
SCHEMBL6347856 0.76 ALDH1A1 (0.43) KMT2AALDH1A1MEN1KDM4EMAPK1
SCHEMBL6347733 0.76 ALDH1A1 (0.43) KMT2AALDH1A1MEN1KDM4EMAPK1
SCHEMBL6354208 0.76 ALDH1A1 (0.43) KMT2AALDH1A1MEN1KDM4EMAPK1
SCHEMBL6352412 0.76 KMT2A (0.43) KMT2AALDH1A1MEN1KDM4ESCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 KMT2A 3612/4885ALDH1A1 420/4885MEN1 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.